within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX03_Catumaxomab;
model Catumaxomab 
   extends Pharmacolibrary.Drugs.ATC.L.L01FX03;

  annotation(Documentation(
    info ="<html><body><p>Catumaxomab is a trifunctional monoclonal antibody used in the treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. It acts by binding to EpCAM on tumor cells, CD3 on T-cells, and Fcγ receptors on accessory cells to induce tumor cell lysis. It was granted orphan drug status and previously approved in the EU but marketing authorization was withdrawn in 2017; it is not currently approved for routine clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimation in adult cancer patients after intraperitoneal (i.p.) administration, as data from original studies is scarce and no human PK model with explicit compartmental parameters is published.</p><h4>References</h4><ol><li><p>Ruf, P, et al., &amp; Lindhofer, H (2010). Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. <i>British journal of clinical pharmacology</i> 69(6) 617–625. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2010.03635.x&quot;>10.1111/j.1365-2125.2010.03635.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20565453/&quot;>https://pubmed.ncbi.nlm.nih.gov/20565453</a></p></li><li><p>Sebastian, M, et al., &amp; Schmittel, A (2009). Catumaxomab: a bispecific trifunctional antibody. <i>Drugs of today (Barcelona, Spain : 1998)</i> 45(8) 589–597. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19927225/&quot;>https://pubmed.ncbi.nlm.nih.gov/19927225</a></p></li><li><p>Bokemeyer, C (2010). Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites. <i>Expert opinion on biological therapy</i> 10(8) 1259–1269. DOI:<a href=&quot;https://doi.org/10.1517/14712598.2010.504706&quot;>10.1517/14712598.2010.504706</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20624115/&quot;>https://pubmed.ncbi.nlm.nih.gov/20624115</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Catumaxomab;
